Drawing for ONCOGNOSIS

USPTO serial 78280702

ONCOGNOSIS

Reviewed by CopyMark Law Group

Reg. 2906475Status 710
Filing date
Status date
Registration date
Nov 30, 2004
Examiner
BERK, STEVEN R
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with ONCOGNOSIS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Catherine Mennenga

CATHERINE MENNENGA GENERAL ELECTRIC COMPANY3135 EASTON TPKEFAIRFIELD, CT 06828-0001UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemicals, biochemicals and reagents for use in industry, science and research, namely, nucleotides, fluorescent nucleotides, oligonucleotides, peptides, proteins, amino acids, organic molecules, markers for DNA/RNA synthesis; reagents for luminescence; reagents for gene expression quantification; reagents for use with polymerase chain reaction, PCR, process and the rolling circle amplification (RCA) process; reagents for cDNA cloning vectors, modifying and restriction enzymes; reagents for labeling, detecting sequencing and fragment analysis of nucleic acids, proteins, and custom synthesis; reagents for recombinant protein expression purification, chromatography media; electrophoresis; spectrophotometry and fluorometry; radiochemicals; scintillation assays; and high through put screening assays for drug development; and chemical preparations and substances for use in the manufacture of pharmaceutical products; diagnostic preparations and substances; chemical test reagents, saline solution and reagent-coated paper, all for scientific and laboratory use; fissionable chemical elements; radioactive elements and isotopes for industrial, scientific, and research purposes; radioactive sources and standards for use in radiographic techniques; radioactive sources for use in non-destructive testing, purification or sterilizing techniques for use in industry, science and research; chemical preparations, kits and reagents for analysis or diagnosis used for scientific purposes, namely, cell separation and culture; nucleic acid purification; and radionuclides, gases and gas mixtures for industrial, scientific, and research purposesSECTION 8 - CANCELLED—
005Diagnostic agents, preparations and substances for medical purposes; Contrast media for medical imaging; diagnostic scanning agents for in vivo use; radiopharmaceutical products for clinical, medical and research use; radioactive sources and standards for use in nuclear medicine; radioactive pharmaceutical preparations and non-radioactive reagents for producing radiopharmaceuticals for in vivo diagnostic or therapeutic use; pharmaceutical preparations for use in diagnosis; pre-filled vials and cartridges containing medical diagnostic reagents or saline solution; and radioisotope brachytherapy substancesSECTION 8 - CANCELLED—
009Scientific apparatus and instruments used for radiology for the purpose of measuring, monitoring and surveying; computers, printers, and software programs used for the purpose of life science research and for nuclear cardiology and medical imaging, for use by laboratories, pharmacies, doctors, hospitals, and medical service providers; radiology apparatus and instruments for the reading and interpretation of autoradiographs and films, namely automated film readers and scanners; apparatus for electrophoresis; chromatography columns and pumps; apparatus for microfabrication; apparatus for scintillation; imaging apparatus for radioactive and luminescent emissions; synthesis and purification integrated systems for use in radiology; apparatus for manufacturing oligonucleotides; apparatus for microarrays; microarray slides; laboratory glassware; laboratory vials and microvials; microtitre plates; and parts and fittings for the aforesaid goodsSECTION 8 - CANCELLED—
010Surgical, medical, dental, and veterinary apparatus and instruments used for the purpose of measuring, monitoring and surveying in the field of radiotherapy, comprised of medical needles, suture needles, implantable radiation therapy devices and implantable radiation therapy devices consisting of encapsulated radioisotope brachytherapy sources, radiation therapy delivery system consisting primarily of radioactive seeds and a bio-absorbable carrier assembly; magnetic resonance imagers, MRI; x-ray apparatus for medical use; x-ray diagnostic apparatus, computerized tomography, CAT scanners and ultrasound imagers; radiological apparatus for diagnostic and medical purposes; diagnostic and test kits for clinical medical use comprised of test tubes, test plates and indicator charts for evaluating test results; vials; cannulas; needles and syringes; injectors; cartridges; infusion pumps for intravenous administration of fluids; needles for medical purposes; and parts and fittings for the aforesaid goodsSECTION 8 - CANCELLED—
042Advisory services for pharmaceutical companies in the field of purification and chromatography; research and development services in the field of pharmaceutical and life sciences; research and product development for others, namely research and development of pharmaceutical, medical, and veterinary preparations, diagnostic media and agents for use in medical and diagnostic imaging; consultancy services relating to chemical and pharmaceutical research; analytical services in the fields of medicine, pharmaceuticals and biochemistry; radiolableling services, namely isotopic labeling of biological molecules; pharmaceutical drug development services for pharmaceutical companies and medical professionalsSECTION 8 - CANCELLED—
044Medical diagnostic services; medical imaging services; providing medical and medical product information to pharmaceutical companies and medical professionalsSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 1, 2011C8..CANCELLED SEC. 8 (6-YR)—
Feb 17, 2005ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 17, 2005REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 30, 2004R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 7, 2004PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 18, 2004NPUBNOTICE OF PUBLICATION—
Jun 16, 2004MAILPAPER RECEIVED—
May 18, 2004CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 19, 20041.BDSec. 1(B) CLAIM DELETED—
Mar 19, 2004CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 19, 2004MAILPAPER RECEIVED—
Jan 20, 2004GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 13, 2004DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance